📊 BRGX Key Takeaways
Investment Thesis
BioRegenx is a financially distressed company with negative stockholders' equity of -$3.6M, liabilities exceeding assets by over 4x, and severe liquidity constraints (current ratio of 0.07x). Despite a healthy 80.7% gross margin, the company is unprofitable at the operating level (-21% margin) and burning cash with negative operating and free cash flows, indicating fundamental business model challenges beyond cost of goods sold.
BRGX Strengths
- High gross margin of 80.7% suggests strong product pricing power or efficient production
- Small revenue base of $1.5M provides potential runway if business can stabilize
- Service sector positioning in computer programming may have growth potential if company survives
BRGX Risks
- Negative stockholders' equity of -$3.6M indicates technical insolvency and high bankruptcy risk
- Critical liquidity crisis with current ratio of 0.07x and only $46.9K cash against $4.8M liabilities
- Negative operating cash flow of -$30.7K and free cash flow of -$36.7K show unsustainable burn rate
- Operating losses of -$308.3K on $1.5M revenue demonstrate inability to scale profitably
- High long-term debt of $1.1M with negative interest coverage of -1.4x raises default risk
Key Metrics to Watch
- Stockholders' equity trend - any movement toward positive equity would signal turnaround
- Operating cash flow - must reach breakeven to demonstrate business sustainability
- Total liabilities vs total assets - current 4:1 ratio is critical distress indicator
- Quarterly revenue growth - needed to justify continued operations
- Cash runway - with current burn rate, assess months of remaining liquidity
BRGX Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BRGX Profitability Ratios
BRGX vs Technology Sector
How BIOREGENX, INC. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BRGX Balance Sheet & Liquidity
BRGX 5-Year Financial Trend
5-Year Trend Summary: BIOREGENX, INC.'s revenue has grown significantly by 1,618% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
BRGX Growth Metrics (YoY)
BRGX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $507.8K | -$80.6K | $0.00 |
| Q2 2025 | $446.0K | -$178.3K | $0.00 |
| Q1 2025 | $515.1K | -$266.9K | $0.00 |
| Q3 2024 | $596.0K | -$394.9K | $0.00 |
| Q2 2024 | $734.0K | -$594.5K | $0.00 |
| Q3 2023 | $3.7K | -$2.2K | $0.00 |
| Q2 2023 | $7.9K | -$4.1K | $0.00 |
| Q1 2023 | $5.6K | -$37.3K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BRGX Capital Allocation
BRGX SEC Filings
Access official SEC EDGAR filings for BIOREGENX, INC. (CIK: 0001593184)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRGX
What is the AI rating for BRGX?
BIOREGENX, INC. (BRGX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRGX's key strengths?
High gross margin of 80.7% suggests strong product pricing power or efficient production. Small revenue base of $1.5M provides potential runway if business can stabilize.
What are the risks of investing in BRGX?
Negative stockholders' equity of -$3.6M indicates technical insolvency and high bankruptcy risk. Critical liquidity crisis with current ratio of 0.07x and only $46.9K cash against $4.8M liabilities.
What is BRGX's revenue and growth?
BIOREGENX, INC. reported revenue of $1.5M.
Does BRGX pay dividends?
BIOREGENX, INC. does not currently pay dividends.
Where can I find BRGX SEC filings?
Official SEC filings for BIOREGENX, INC. (CIK: 0001593184) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRGX's EPS?
BIOREGENX, INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.